BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Eur...
Tensor Trader on BioMarin Pharmaceutical Inc. (BMRN)
主要经营地
美国加州 San Rafael
详细的生意模式
专注罕见病商业化与研发，依靠酶替代治疗、VOXZOGO 等已上市产品获取高毛利现金流，再通过管线推进和并购（Amicus）扩充品类与全球覆盖。
护城河
✅ 罕见病赛道的注册、商业化、医保与全球渠道能力；✅ 多个成熟产品构成现金流基座；✅ Orphan drug 属性提升定价与黏性。❌ 管线与并购整合仍带来执行风险。
估值水平
FCF/EV 3.7%
EV/Market Cap
0.92x
网络观点
作者认为市场低估了 BioMarin：Q4/FY2025 收入强于预期，VOXZOGO 继续高增长，现金流显著改善，而 Amicus 收购在其框架里属于“付钱买成熟增长”，并非盲目扩张，因此给出 86 美元目标价。
AI的观点
官方结果显示，这已经不是“靠故事活着”的 biotech，而是真正能产生大量经营现金流的罕见病平台。Amicus 并购会增加杠杆，但也明显丰富了商业组合。相比很多高估值成长股，BioMarin 的吸引力在于：业务质量高、现金流真实、估值也没有离谱。若在 Part 1 里挑大中型、偏稳健的价值/GARP 标的，它是我会放在前列的一家。
作者简介
Quantamental 风格通讯，将价值、质量、动量因子与基本面催化和宏观视角结合。
官方一手资料
Q4/FY2025 Results：https://investors.biomarin.com/news/news-details/2026/BioMarin-Reports-Fourth-Quarter-and-Full-year-2025-Financial-and-Operating-Results/default.aspx ; Amicus acquisition PR：https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx
原文标题
Quarterly Update: BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical (BMRN): An Asymmetric Opportunity at $59
BioMarin is undervalued due to market pessimism. The acquisition of Amicus Therapeutics and the divestment of Roctavian are positive catalysts. The company has a strong portfolio of rare disease drugs and is targeting 40% operating margins. The price target is $86, representing a 45% upside.